DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for narcolepsy — screening already-approved drugs against its 33-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNarcolepsy maps to a 33-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for narcolepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
LYR motif containing 4 (LYRM4) — LYRM4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6UXE · 1.57 Å · ligand PYRIDOXAL-5'-PHOSPHATE (PLP). Experimental structure, not a prediction.
What the evidence adds up to
A 12-month open-label extension trial of sodium oxybate in 118 narcolepsy patients who had completed a prior 4-week double-blind trial reported improvements in symptoms. Patients took 3 to 9 g nightly, with the dose adjusted in 1.5 g increments. The primary measure was change in weekly cataplexy attacks, and secondary measures included the Epworth Sleepiness Scale, inadvertent naps, nighttime awakenings, and the Clinical Global Impression of Change. The authors state that improvements in cataplexy frequency, daytime sleepiness, nocturnal sleep quality, alertness, and concentration were significant at 4 weeks and maximal after 8 weeks, with p values below 0.001 for each. Adverse events were described as generally mild, and no evidence of tolerance was observed. The conclusion was that sodium oxybate is effective and well-tolerated.
A 2016 genetic study analysed HLA class I and II genotypes in 944 European narcolepsy with cataplexy patients and 4,043 controls, all positive for DQB1*06:02. The study found associations between narcolepsy susceptibility and HLA-A*11:01 (odds ratio 1.49), C*04:01 (odds ratio 1.34), and B*35:01 (odds ratio 1.46). Stronger associations were seen with specific antigen-binding residues: HLA-A-Tyr9 (odds ratio 1.32) and HLA-C-Ser11 (odds ratio 1.34). The authors argue that because neurons express class I but not class II molecules, these findings suggest a cytotoxic mechanism involving CD8+ T cells or NK cells as the final step in hypocretin neuron destruction. They note that functional data are still missing and that no CD4+ T-cell mechanism or inflammation has been corroborated despite the strong HLA class II association.
A 2015 narrative review states that current narcolepsy treatments are often unsatisfactory due to suboptimal efficacy, side effects, tolerance, and inconvenience. It notes that understanding of narcolepsy neurobiology has improved but has not yet produced additional therapeutic options. The review mentions histaminergic H3 receptor antagonists as potentially useful for symptom control and says hypocretin replacement therapy offers some promise, but a cure still seems distant. A 2018 article describes available options as a combination of medication, scheduled naps, and acceptance, and states that a cure or early diagnosis to halt progression feels very far off. It adds that because narcolepsy is an orphan disease, effective medications primarily benefit patent holders, and many patients are denied access due to inflated drug prices.
What is still missing is a disease-modifying or curative treatment. No therapy has been shown to prevent or reverse hypocretin neuron loss. The genetic evidence for a cytotoxic immune mechanism lacks functional confirmation. No large, randomised, placebo-controlled trial has tested any immune-modulating agent in early narcolepsy. Hypocretin replacement remains experimental and has not been tested in a definitive phase 3 trial. The high cost of existing drugs and the orphan drug regulatory framework create access barriers that are not addressed by current research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
SLEEP · 2003 · 148 citations · open access
A 12-month, Open-Label, Multicenter Extension Trial of Orally Administered Sodium Oxybate for the Treatment of Narcolepsy
AbstractOBJECTIVES: To evaluate the long-term safety and efficacy of nightly sodium oxybate for the treatment of narcolepsy. DESIGN: A multicenter, 12-month, open-label trial. PARTICIPANTS: 118 narcolepsy patients previously enrolled in a 4-week double-blind sodium oxybate trial. INTERVENTIONS: Patients were administered 6 g sodium oxybate nightly, taken in equally divided doses at bedtime and 2.5 to 4 hours later. The study protocol permitted the dose to be increased or decreased in 1.5-g increments at 2-week intervals based on efficacy response or adverse experiences but staying within the range of 3 to 9 g nightly. MEASURES: Narcolepsy symptoms and adverse events were recorded in daily diaries. Safety measures included physical and laboratory examinations repeated at 6 and 12 months. The primary efficacy measure was the change in weekly cataplexy attacks from baseline. Secondary measures included daytime sleepiness using the Epworth Sleepiness Scale (ESS), inadvertent naps/sleep attacks, nighttime awakenings, and the overall change in disease severity as rated by the investigators (Clinical Global Impression of Change; CGI-c). RESULTS: Sodium oxybate, in doses of 3 to 9 g nightly, produced overall improvements in narcolepsy symptoms, which were significant at 4 weeks and maximal after 8 weeks. Reported improvements included a significant decrease in frequency of cataplexy attacks (p < 0.001); diminished daytime sleepiness (p < 0.001); and patient descriptions of nocturnal sleep quality, level of alertness, and ability to concentrate (for each p < 0.001). Adverse events were generally mild and patients showed no evidence of tolerance. CONCLUSION: Sodium oxybate is an effective and well-tolerated treatment for narcolepsy.
Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity
AbstractNarcolepsy with cataplexy is tightly associated with the HLA class II allele DQB1*06:02. Evidence indicates a complex contribution of HLA class II genes to narcolepsy susceptibility with a recent independent association with HLA-DPB1. The cause of narcolepsy is supposed be an autoimmune attack against hypocretin-producing neurons. Despite the strong association with HLA class II, there is no evidence for CD4+ T-cell-mediated mechanism in narcolepsy. Since neurons express class I and not class II molecules, the final effector immune cells involved might include class I-restricted CD8+ T-cells. HLA class I (A, B, and C) and II (DQB1) genotypes were analyzed in 944 European narcolepsy with cataplexy patients and in 4,043 control subjects matched by country of origin. All patients and controls were DQB1*06:02 positive and class I associations were conditioned on DQB1 alleles. HLA-A*11:01 (OR = 1.49 [1.18–1.87] P = 7.0*10−4), C*04:01 (OR = 1.34 [1.10–1.63] P = 3.23*10−3), and B*35:01 (OR = 1.46 [1.13–1.89] P = 3.64*10−3) were associated with susceptibility to narcolepsy. Analysis of polymorphic class I amino-acids revealed even stronger associations with key antigen-binding residues HLA-A-Tyr9 (OR = 1.32 [1.15–1.52] P = 6.95*10−5) and HLA-C-Ser11 (OR = 1.34 [1.15–1.57] P = 2.43*10−4). Our findings provide a genetic basis for increased susceptibility to infectious factors or an immune cytotoxic mechanism in narcolepsy, potentially targeting hypocretin neurons. Although evidence strongly indicates that immune-related mechanisms are involved in the pathogenesis of narcolepsy with hypocretin deficiency, functional data are missing. The strong association with HLA class II genes is not corroborated by any CD4+ T Cell implication and inflammation. Additionally, these genes are not normally expressed in the brain. Here, we show that several HLA class I variants are associated with narcolepsy. Since these molecules are expressed in the brain, our results suggest that a cytotoxic (CD8+ T Cell or NK cell) mechanism might be the final step in the disease, leading to hypocretin neuronal destruction.
Nature and Science of Sleep · 2015 · 26 citations · open access
Unmet needs of patients with narcolepsy: perspectives on emerging treatment options
AbstractThe treatment options currently available for narcolepsy are often unsatisfactory due to suboptimal efficacy, troublesome side effects, development of drug tolerance, and inconvenience. Our understanding of the neurobiology of narcolepsy has greatly improved over the last decade. This knowledge has not yet translated into additional therapeutic options for patients, but progress is being made. Some compounds, such as histaminergic H3 receptor antagonists, may prove useful in symptom control of narcolepsy. The prospect of finding a cure still seems distant, but hypocretin replacement therapy offers some promise. In this narrative review, we describe these developments and others which may yield more effective narcolepsy treatments in the future.
Oxford University Press eBooks · 2018 · 0 citations
Narcolepsy
AbstractNarcolepsy is a fascinating disease for many, less so if you develop it yourself. Current options available to patients involve a less-than-subtle combination of medication, snatched periods of sleep, a large degree of acceptance that this is how life is with narcolepsy, and the tolerance of family, friends, and employers. In 2016, the focus is on the treatment of symptoms. A cure, or even a process, for early diagnosis and subsequent halting of progression feels very far off. Owing to the orphan disease status of narcolepsy, the main beneficiaries of effective medication remain the patent holders, with many patients, whether in private healthcare systems in the USA or the National Health Service in the UK, prevented from access on account of inflated drug prices.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
